Methylprednisolone is a potent synthetic glucocorticoid, a derivative of prednisolone, with significant anti-inflammatory, immunosuppressive, and anti-allergic properties. The 40mg/ml concentration is a high-strength formulation primarily used for intravenous or intramuscular administration in hospital settings for severe, acute conditions. It is approximately 1.25 times more potent than prednisolone and 5 times more potent than hydrocortisone. In India, it is a critical drug for managing acute exacerbations of autoimmune diseases, severe allergic reactions, and as part of chemotherapeutic regimens.
Adult: Dose varies widely by indication. Initial: 10-40mg IV/IM, repeated every 4-6 hrs as needed. High-dose/Pulse: 500mg to 1g IV daily for 3-5 days for conditions like lupus nephritis. Spinal Cord Injury: 30mg/kg IV bolus over 15 min, followed by 5.4mg/kg/hr infusion for 23 hrs (NASCIS II protocol). Cerebral Edema: 40-250mg IV, then 40-100mg IV every 4-6 hrs.
Note: For IV use: Methylprednisolone sodium succinate (40mg/ml) must be reconstituted/diluted. Can be given as a slow IV push over 2-5 minutes (for doses ā¤125mg) or as an IV infusion in compatible solutions (NS, D5W) over 15-60 minutes for higher doses to avoid arrhythmias. IM: Administer deep into gluteal muscle. DO NOT give subcutaneously. Inspect solution for particulate matter. Avoid abrupt withdrawal after prolonged use (>2 weeks).
Methylprednisolone diffuses across cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. The activated receptor-ligand complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA, modulating gene transcription. This leads to increased synthesis of anti-inflammatory proteins (e.g., lipocortin-1, IĪŗBĪ±) and decreased synthesis of pro-inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules, enzymes like COX-2). It also induces apoptosis of lymphocytes.
Pregnancy: US FDA Category C. May be used if potential benefit justifies risk. Crosses placenta. Chronic use in 1st trimester associated with cleft palate risk. Use in 3rd trimester may cause fetal adrenal suppression. Monitor neonate for hypoadrenalism. Indian guidelines recommend use only for life-threatening maternal conditions.
Driving: May cause dizziness, vertigo, or visual disturbances. Caution advised when driving or operating machinery, especially at therapy initiation.
| Warfarin/Acenoocumarol | Altered INR (may increase or decrease); monitor closely. | Major |
| Phenytoin, Phenobarbital, Rifampicin | Increased hepatic metabolism of methylprednisolone, reducing its efficacy. Dose increase may be needed. | Major |
| Ketoconazole, Itraconazole, Clarithromycin | CYP3A4 inhibitors; decrease metabolism of methylprednisolone, increasing toxicity risk. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of GI ulceration and bleeding. | Major |
| Diuretics (e.g., Furosemide, Hydrochlorothiazide) | Enhanced potassium loss, severe hypokalemia. | Major |
| Insulin, Oral Hypoglycemics | Corticosteroid-induced hyperglycemia may require dose adjustment of anti-diabetic drugs. | Moderate |
| Vaccines (Live-attenuated) | Diminished antibody response, risk of disseminated infection. | Major |
| Digoxin | Increased risk of digoxin toxicity due to hypokalemia. | Moderate |
Same composition (Methylprednisolone (40mg/ml)), different brands: